Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy

Matthew R. Cooperberg, Stephen J. Freedland, David J. Pasta, Eric P. Elkin, Joseph C. Presti, Christopher L. Amling, Martha Kennedy Terris, William J. Aronson, Christopher J. Kane, Peter R. Carroll

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

BACKGROUND. The University of California, San Francisco (UCSF) Cancer of the Prostate Risk Assessment (CAPRA) is a novel preoperative index which predicts the risk of biochemical recurrence after radical prostatectomy. The performance of the index is at least as good as the best available instruments based on clinical variables, and the 0 to 10 score is simple to calculate for both clinical and research purposes. This study used a large external dataset to validate CAPRA. METHODS. Data were abstracted from the Shared Equal Access Regional Cancer Hospital (SEARCH) database, a registry of men who underwent radical prostatectomy at 4 Veterans Affairs and 1 active military medical center. Of 2096 men in the database, 1346 (64%) had full data available to calculate the CAPRA score. Performance of the CAPRA score was assessed with proportional hazards regression, survival analysis, and the concordance (c) index. RESULTS. Of the studied patients, 41% were non-Caucasian, and their mean age was 62 years. Twenty-six percent suffered recurrence; median follow-up among patients who did not recur was 34 months. The hazard ratio (HR) for each 1-point increase in CAPRA was 1.39 (95% CI [confidence interval], 1.31-1.46). The 5-year recurrence-free survival rate ranged from 86% for CAPRA 0-1 patients to 21% for CAPRA 7-10 patients. Increasing CAPRA scores were significantly associated with increasing risk of adverse pathologic outcomes. The c-index for CAPRA for the validation set was 0.68, compared with 0.66 for the original development set. CONCLUSIONS. The UCSF-CAPRA accurately predicted both biochemical and pathologic outcomes after radical prostatectomy among a large, diverse, cohort of men. These results validated the effectiveness of this powerful and straightforward instrument.

Original languageEnglish (US)
Pages (from-to)2384-2391
Number of pages8
JournalCancer
Volume107
Issue number10
DOIs
StatePublished - Nov 15 2006

Fingerprint

San Francisco
Prostatectomy
Prostatic Neoplasms
Recurrence
Databases
Cancer Care Facilities
Veterans
Survival Analysis
Registries
Survival Rate
Regression Analysis
Confidence Intervals

Keywords

  • Prognosis
  • Prostate neoplasm
  • Prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cooperberg, M. R., Freedland, S. J., Pasta, D. J., Elkin, E. P., Presti, J. C., Amling, C. L., ... Carroll, P. R. (2006). Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer, 107(10), 2384-2391. https://doi.org/10.1002/cncr.22262

Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. / Cooperberg, Matthew R.; Freedland, Stephen J.; Pasta, David J.; Elkin, Eric P.; Presti, Joseph C.; Amling, Christopher L.; Terris, Martha Kennedy; Aronson, William J.; Kane, Christopher J.; Carroll, Peter R.

In: Cancer, Vol. 107, No. 10, 15.11.2006, p. 2384-2391.

Research output: Contribution to journalArticle

Cooperberg, MR, Freedland, SJ, Pasta, DJ, Elkin, EP, Presti, JC, Amling, CL, Terris, MK, Aronson, WJ, Kane, CJ & Carroll, PR 2006, 'Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy', Cancer, vol. 107, no. 10, pp. 2384-2391. https://doi.org/10.1002/cncr.22262
Cooperberg, Matthew R. ; Freedland, Stephen J. ; Pasta, David J. ; Elkin, Eric P. ; Presti, Joseph C. ; Amling, Christopher L. ; Terris, Martha Kennedy ; Aronson, William J. ; Kane, Christopher J. ; Carroll, Peter R. / Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. In: Cancer. 2006 ; Vol. 107, No. 10. pp. 2384-2391.
@article{2baf0a232358419db3b761a6a8132925,
title = "Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy",
abstract = "BACKGROUND. The University of California, San Francisco (UCSF) Cancer of the Prostate Risk Assessment (CAPRA) is a novel preoperative index which predicts the risk of biochemical recurrence after radical prostatectomy. The performance of the index is at least as good as the best available instruments based on clinical variables, and the 0 to 10 score is simple to calculate for both clinical and research purposes. This study used a large external dataset to validate CAPRA. METHODS. Data were abstracted from the Shared Equal Access Regional Cancer Hospital (SEARCH) database, a registry of men who underwent radical prostatectomy at 4 Veterans Affairs and 1 active military medical center. Of 2096 men in the database, 1346 (64{\%}) had full data available to calculate the CAPRA score. Performance of the CAPRA score was assessed with proportional hazards regression, survival analysis, and the concordance (c) index. RESULTS. Of the studied patients, 41{\%} were non-Caucasian, and their mean age was 62 years. Twenty-six percent suffered recurrence; median follow-up among patients who did not recur was 34 months. The hazard ratio (HR) for each 1-point increase in CAPRA was 1.39 (95{\%} CI [confidence interval], 1.31-1.46). The 5-year recurrence-free survival rate ranged from 86{\%} for CAPRA 0-1 patients to 21{\%} for CAPRA 7-10 patients. Increasing CAPRA scores were significantly associated with increasing risk of adverse pathologic outcomes. The c-index for CAPRA for the validation set was 0.68, compared with 0.66 for the original development set. CONCLUSIONS. The UCSF-CAPRA accurately predicted both biochemical and pathologic outcomes after radical prostatectomy among a large, diverse, cohort of men. These results validated the effectiveness of this powerful and straightforward instrument.",
keywords = "Prognosis, Prostate neoplasm, Prostatectomy",
author = "Cooperberg, {Matthew R.} and Freedland, {Stephen J.} and Pasta, {David J.} and Elkin, {Eric P.} and Presti, {Joseph C.} and Amling, {Christopher L.} and Terris, {Martha Kennedy} and Aronson, {William J.} and Kane, {Christopher J.} and Carroll, {Peter R.}",
year = "2006",
month = "11",
day = "15",
doi = "10.1002/cncr.22262",
language = "English (US)",
volume = "107",
pages = "2384--2391",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy

AU - Cooperberg, Matthew R.

AU - Freedland, Stephen J.

AU - Pasta, David J.

AU - Elkin, Eric P.

AU - Presti, Joseph C.

AU - Amling, Christopher L.

AU - Terris, Martha Kennedy

AU - Aronson, William J.

AU - Kane, Christopher J.

AU - Carroll, Peter R.

PY - 2006/11/15

Y1 - 2006/11/15

N2 - BACKGROUND. The University of California, San Francisco (UCSF) Cancer of the Prostate Risk Assessment (CAPRA) is a novel preoperative index which predicts the risk of biochemical recurrence after radical prostatectomy. The performance of the index is at least as good as the best available instruments based on clinical variables, and the 0 to 10 score is simple to calculate for both clinical and research purposes. This study used a large external dataset to validate CAPRA. METHODS. Data were abstracted from the Shared Equal Access Regional Cancer Hospital (SEARCH) database, a registry of men who underwent radical prostatectomy at 4 Veterans Affairs and 1 active military medical center. Of 2096 men in the database, 1346 (64%) had full data available to calculate the CAPRA score. Performance of the CAPRA score was assessed with proportional hazards regression, survival analysis, and the concordance (c) index. RESULTS. Of the studied patients, 41% were non-Caucasian, and their mean age was 62 years. Twenty-six percent suffered recurrence; median follow-up among patients who did not recur was 34 months. The hazard ratio (HR) for each 1-point increase in CAPRA was 1.39 (95% CI [confidence interval], 1.31-1.46). The 5-year recurrence-free survival rate ranged from 86% for CAPRA 0-1 patients to 21% for CAPRA 7-10 patients. Increasing CAPRA scores were significantly associated with increasing risk of adverse pathologic outcomes. The c-index for CAPRA for the validation set was 0.68, compared with 0.66 for the original development set. CONCLUSIONS. The UCSF-CAPRA accurately predicted both biochemical and pathologic outcomes after radical prostatectomy among a large, diverse, cohort of men. These results validated the effectiveness of this powerful and straightforward instrument.

AB - BACKGROUND. The University of California, San Francisco (UCSF) Cancer of the Prostate Risk Assessment (CAPRA) is a novel preoperative index which predicts the risk of biochemical recurrence after radical prostatectomy. The performance of the index is at least as good as the best available instruments based on clinical variables, and the 0 to 10 score is simple to calculate for both clinical and research purposes. This study used a large external dataset to validate CAPRA. METHODS. Data were abstracted from the Shared Equal Access Regional Cancer Hospital (SEARCH) database, a registry of men who underwent radical prostatectomy at 4 Veterans Affairs and 1 active military medical center. Of 2096 men in the database, 1346 (64%) had full data available to calculate the CAPRA score. Performance of the CAPRA score was assessed with proportional hazards regression, survival analysis, and the concordance (c) index. RESULTS. Of the studied patients, 41% were non-Caucasian, and their mean age was 62 years. Twenty-six percent suffered recurrence; median follow-up among patients who did not recur was 34 months. The hazard ratio (HR) for each 1-point increase in CAPRA was 1.39 (95% CI [confidence interval], 1.31-1.46). The 5-year recurrence-free survival rate ranged from 86% for CAPRA 0-1 patients to 21% for CAPRA 7-10 patients. Increasing CAPRA scores were significantly associated with increasing risk of adverse pathologic outcomes. The c-index for CAPRA for the validation set was 0.68, compared with 0.66 for the original development set. CONCLUSIONS. The UCSF-CAPRA accurately predicted both biochemical and pathologic outcomes after radical prostatectomy among a large, diverse, cohort of men. These results validated the effectiveness of this powerful and straightforward instrument.

KW - Prognosis

KW - Prostate neoplasm

KW - Prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=33751010199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751010199&partnerID=8YFLogxK

U2 - 10.1002/cncr.22262

DO - 10.1002/cncr.22262

M3 - Article

VL - 107

SP - 2384

EP - 2391

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -